Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Date:11/6/2012

SAN FRANCISCO, Nov. 6, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2012 on Tuesday, November 13, 2012, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Thursday, December 13, 2012.

To access the conference call, follow these instructions:

Dial: (877) 881-2183  (U.S.); (970) 315-0453 (international)
Passcode: 50562038 (Nektar Therapeutics is the host)

An audio replay will also be available shortly following the call through Thursday, December 13, 2012 and can be accessed by dialing (855) 859-2056 (U.S.); or (404) 537-3406 (international) with a passcode of 50562038.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which has completed Phase 1/2 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-415-482-5585


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
2. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
3. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
4. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
5. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
9. Perrigo Company Announces Appointment Of New Board Of Directors Member
10. Rochester Medical Corporation Announces Decision To Exit The Foley Catheter Business
11. Webcast Alert: Heska Announces Third Quarter 2012 Earnings Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... Monday, August 14 and host a conference call at ... 2017 operating and financial results and its strategy and ... be hosted by Erez Raphael , Chief Executive ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million ... continuing operations Second-quarter 2017 ... million Second-quarter 2017 Sterile ... Second-quarter 2017 adjusted diluted earnings ... to $0.93 Second-quarter 2017 ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... TopConsumerReviews.com recently gave a best-in-class ... Fatigue . , As the stress of modern life continually makes more demands on ... use of artificial stimulants can trap people in vicious high/low cycles and can also ...
(Date:8/21/2017)... City, NY (PRWEB) , ... August 22, 2017 ... ... honors Judith I. Stevens as a 2017-2018 inductee into its ... for leadership in entrepreneurship. NAPW is the nation’s leading networking organization exclusively for ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... taking place all over the country. , Outdoor running increases exposure to ultraviolet ... at an increased risk of melanoma, and only half may be adequately protecting ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and ... care reform plan, has announced his candidacy for the 52nd Congressional District currently held ... in America’s Promise. Coming to this country at age eleven after suffering homelessness and ...
(Date:8/20/2017)... ... ... State Farm Neighborhood Assist® has named The Southern Maryland Team Anti-Bullying ... the initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl program to ... Mary’s, Calvert and Charles Counties. The program could potentially impact nearly 17,500 female students ...
Breaking Medicine News(10 mins):